開設賬戶
模擬帳戶
關於我們
即時報價及新聞
市場分析
財經日曆
每日市場分析
交易平台
下載及介紹
使用教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
繁
简
EN
客户登入
開設賬戶
模擬帳戶
繁
简
EN
客户登入
開設賬戶
模擬帳戶
關於我們
上志國際介紹
上志國際特點
即時報價及新聞
即時報價
即時新聞
市場分析
財經日曆
市場分析
交易平台
平台特點
平台教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
關於我們
交易細則
貴金屬市場
交易平台
市場分析
推廣和資訊
常見問題
聯絡我們
繁
简
EN
Bank of England consumer credit, April: £1.859 bln vs expected £1.70 bln; March revised to £1.904 bln from £1.895 bln.
2026-06-02
Bank of England consumer credit, April: £1.859 bln vs expected £1.70 bln; March revised to £1.904 bln from £1.895 bln.
返回
其他消息
2026-06-01
據國際文傳電訊社:俄羅斯核監管機構負責人利哈喬夫與國際原子能機構總幹事格羅西就扎波羅熱核電站的情況進行了會談。
據國際文傳電訊社:俄羅斯核監管機構負責人利哈喬夫與國際原子能機構總幹事格羅西就扎波羅熱核電站的情況進行了會談。
2026-06-02
Everest Medicines said it has struck an exclusive licence and collaboration with Travere Therapeutics granting Travere exclusive development and commercial rights to EVER001 (civorebrutinib) outside Greater China and certain Southeast Asian countries. Everest will receive a $112.5m upfront payment and is eligible for up to $1.03bn in development, regulatory and commercial milestone payments across up to five indications, plus tiered royalties on future annual net sales ranging from high-single-d
Everest Medicines said it has struck an exclusive licence and collaboration with Travere Therapeutics granting Travere exclusive development and commercial rights to EVER001 (civorebrutinib) outside Greater China and certain Southeast Asian countries. Everest will receive a $112.5m upfront payment and is eligible for up to $1.03bn in development, regulatory and commercial milestone payments across up to five indications, plus tiered royalties on future annual net sales ranging from high-single-digit to low-double-digit pct.
Chat with us
, powered by
LiveChat